Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - salazosulfapyridine - yellow to yellowish brown tablet, diameter: 9.7 mm, thickness: 5.0 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - salazosulfapyridine - yellow to yellowish brown tablet, major axis: 18.3 mm, minor axis: 9.8 mm, thickness: 5.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - salazosulfapyridine - yellow to yellow-brown tablet, major axis: approx. 17.2 mm, minor axis: approx. 7.1 mm, thickness: approx. 5.7 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - salazosulfapyridine - brownish-red tablet, diameter: 11.0 mm, thickness: 5.1 mm

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - sulfapyridine - oral capsule - 250mg

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - sulphasalazine - enteric coated tablet - 500 mg - sulphasalazine 500 mg

Canada - English - Health Canada

aventis pharma inc - sulfapyridine - tablet - 500mg - sulfapyridine 500mg - sulfonamides

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - azulfidine en-tabs tablets are indicated: azulfidine en-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, azulfidine en-tabs does not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of azulfidine en-tabs is apparent. azulfidine en-tabs tablets are contraindicated in: hypersensitivity to sulfasalazine, its metabolites, sulfonam

United States - English - NLM (National Library of Medicine)

greenstone llc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine delayed release tablets are indicated: sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent. sulfasalazine delayed release tablets are con

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

ayumi pharmaceutical co., ltd. - salazosulfapyridine - yellow to yellowish brown tablet, major axis: 12.8 mm, minor axis: 6.8 mm